Asthma, Depression, Urticaria
Conditions
Keywords
Depression, Asthma, Urticaria
Brief summary
Depression and other unhealthy behaviors, such as not taking medication as prescribed and not attending doctor visits have been suggested to increase the worsening of allergic diseases (e.g. asthma, urticaria). We intend to determine whether a one-session behavioral intervention is effective in helping with depression and controlling disease symptoms. We will measure this using pre- and post-intervention surveys.
Detailed description
The purpose of this research study is to investigate whether a one-session behavioral activation intervention for depression can successfully reduce depression and improve asthma or urticaria disease-relevant outcomes (medication adherence, doctor's visits, substance abuse) in clinical patients with asthma or urticaria who report heightened levels of depression and are seen in the UMMC Allergy Clinic.
Interventions
BEHAVIORALBrief Behavioral Activation Intervention
Clinical psychologists (investigators) will instruct the participant in ways to become more active in life, particularly with regards to activities that the participant finds pleasurable and meaningful. The intervention will take one hour to complete. Following the intervention, the participant will receive brief, weekly text or email reminders for the next 4 weeks (total of 4) to engage in pleasurable and meaningful activities during the week.
Sponsors
University of Mississippi Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
No
Inclusion criteria
* Potential participants should be between the ages 18 and 64, seen in the UMMC Allergy Clinic with either asthma or urticaria and who report symptoms of depression in the previous 2 weeks.
Exclusion criteria
* Potential participants younger than 18 and older than 64 or who do not speak English or cannot comprehend the consent form or women who are pregnant are excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Asthma Control Test | 4 weeks | Changes in asthma control over a 4 week period. |
| Urticaria Control Test | 4 weeks | Changes in urticaria control over a 4 week period. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Asthma Quality of Life Questionnaire | 4 weeks | Changes in asthma quality of life over a 4 week period. |
| Urticaria Activity Score Questionnaire | 4 weeks | Changes in the activity of urticaria over a 4 week period. |
| Psychological Measures (Composite) | 4 weeks | Effects of brief behavioral activation intervention based upon psychological differences including depression and anxiety measured over a 4 week period. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Immune biomarkers | 4 weeks | Changes in Regulatory T (Treg), Type 1 Regulatory (Tr1), T helper (TH3), T helper 1 (TH1), T helper 2 (TH2), cells, Interferon gamma (IFNg), Interleukin 4 (IL4) and Interleukin 10 (IL10) cytokine production from baseline to 4 weeks. |
Countries
United States
Outcome results
None listed